Xiang Liu to Sphingolipids
This is a "connection" page, showing publications Xiang Liu has written about Sphingolipids.
Connection Strength
1.135
-
Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36.
Score: 0.326
-
Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets. 2010 May; 14(5):529-39.
Score: 0.271
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
Score: 0.210
-
Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma. PLoS One. 2019; 14(4):e0215770.
Score: 0.126
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.066
-
Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008 Jan 15; 16(2):1032-45.
Score: 0.056
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.052
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.014
-
New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006 Aug 21; 580(19):4751-6.
Score: 0.013